FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Lipella Pharmaceuticals Inc. Stock AnalysisComprehensive stock analysis for Lipella Pharmaceuticals Inc. (LIPO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisLIPO
LIPO
Lipella Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
LIPO
Home🔹Stocks🔹Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc.

LIPO•NASDAQ

Lipella Pharmaceuticals Inc.

LIPO•NASDAQ
Market cap
$1.94M
Sentiment

Your view on LIPO

Mkt Cap
$1.94M
Sentiment
Your view
LIPO
Lipella Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
LIPO
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Lipella Pharmaceuticals Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Jonathan Kaufman
Headquarters
7800 Susquehanna St., Pittsburgh, PA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Jonathan Kaufman
Headquarters
7800 Susquehanna St., Pittsburgh, PA, US
Description

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News